JP2021522798A5 - - Google Patents
Info
- Publication number
- JP2021522798A5 JP2021522798A5 JP2020561821A JP2020561821A JP2021522798A5 JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5 JP 2020561821 A JP2020561821 A JP 2020561821A JP 2020561821 A JP2020561821 A JP 2020561821A JP 2021522798 A5 JP2021522798 A5 JP 2021522798A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition according
- express
- antigen
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000389A JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666665P | 2018-05-03 | 2018-05-03 | |
| US62/666,665 | 2018-05-03 | ||
| US201862666965P | 2018-05-04 | 2018-05-04 | |
| US62/666,965 | 2018-05-04 | ||
| PCT/US2019/030721 WO2019213610A1 (en) | 2018-05-03 | 2019-05-03 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Division JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522798A JP2021522798A (ja) | 2021-09-02 |
| JP2021522798A5 true JP2021522798A5 (enExample) | 2022-05-09 |
Family
ID=68386134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561821A Ceased JP2021522798A (ja) | 2018-05-03 | 2019-05-03 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210230548A1 (enExample) |
| EP (1) | EP3788061A4 (enExample) |
| JP (2) | JP2021522798A (enExample) |
| KR (1) | KR20210005240A (enExample) |
| CN (1) | CN112292390A (enExample) |
| AU (1) | AU2019262218B2 (enExample) |
| BR (1) | BR112020022010A2 (enExample) |
| CA (1) | CA3099342A1 (enExample) |
| CO (1) | CO2020015168A2 (enExample) |
| MX (1) | MX2020011697A (enExample) |
| NZ (1) | NZ770183A (enExample) |
| SG (1) | SG11202010763VA (enExample) |
| WO (1) | WO2019213610A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740624B (zh) | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
| PH12014500093A1 (en) | 2011-07-11 | 2014-03-17 | Takeda Vaccines Inc | Parenteral norovirus vaccine formulations |
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| WO2019094725A2 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
| CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| EP3947647A4 (en) * | 2019-03-29 | 2023-01-04 | Board of Regents, The University of Texas System | METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| US12195723B2 (en) * | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| CN110760007B (zh) * | 2019-11-21 | 2022-08-26 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CA3163258A1 (en) * | 2019-11-27 | 2021-06-03 | Board Of Regents, The University Of Texas System | Large-scale combined car transduction and crispr gene editing of nk cells |
| EP4065138A4 (en) * | 2019-11-27 | 2024-02-28 | Board of Regents, The University of Texas System | LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| BR112022013445A2 (pt) * | 2020-01-08 | 2022-09-13 | Univ Texas | Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos |
| JP7773789B2 (ja) | 2020-03-28 | 2025-11-20 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 癌の治療のための細胞免疫療法 |
| WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
| CN113913458A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 非病毒方法制备稳定高表达嵌合受体的nk细胞 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4255453A4 (en) * | 2020-12-03 | 2025-03-26 | Nkarta, Inc. | Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US20240115606A1 (en) | 2020-12-15 | 2024-04-11 | Universiteit Antwerpen | Cell-Based Therapeutics Targeting CD70 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| WO2022173737A1 (en) | 2021-02-09 | 2022-08-18 | Millennium Pharmaceuticals, Inc. | Methods and compositions for freezing and thawing mammalian cells |
| CN113005151A (zh) * | 2021-03-12 | 2021-06-22 | 广东药科大学 | 一种kdr-car-nk细胞的制备方法及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| AU2022266583A1 (en) | 2021-04-26 | 2023-10-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
| WO2022242700A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified nk cells and uses thereof |
| JP2024522756A (ja) * | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| WO2023056330A1 (en) * | 2021-10-01 | 2023-04-06 | Board Of Regents, The University Of Texas System | Antibody loaded immune cells and methods for use in cancer treatment |
| WO2023062113A1 (en) * | 2021-10-15 | 2023-04-20 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
| EP4419541A4 (en) * | 2021-10-21 | 2025-12-17 | Univ Texas | METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL |
| AU2022381757A1 (en) * | 2021-11-04 | 2024-05-09 | Saliogen Therapeutics, Inc. | Immune cells with chimeric antigen receptors or chimeric autoantibody receptors |
| UY40023A (es) | 2021-11-18 | 2023-05-31 | Janssen Biotech Inc | Métodos de cultivo celular sin alimentadora para la expansión de preparaciones de células destructoras naturales |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120152735A (zh) * | 2022-10-25 | 2025-06-13 | 武田药品工业株式会社 | Adgre2嵌合受体nk细胞组合物和使用方法 |
| CN120091827A (zh) * | 2022-11-10 | 2025-06-03 | 昂克医疗有限公司 | 使用免疫调节药物的联合疗法 |
| CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
| CN115948344A (zh) * | 2023-02-10 | 2023-04-11 | 上海交通大学 | 嵌合抗原受体nk细胞、制备方法及其用途 |
| CN116731972A (zh) * | 2023-02-10 | 2023-09-12 | 上海交通大学 | 嵌合抗原受体t细胞、制备方法及其用途 |
| JP2026511162A (ja) * | 2023-03-24 | 2026-04-10 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 強化された抗腫瘍記憶応答を備える操作されたナチュラルキラー細胞 |
| WO2024211554A1 (en) * | 2023-04-07 | 2024-10-10 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| EP4788796A1 (en) * | 2023-10-05 | 2026-08-12 | ONK Therapeutics Limited | Optimised il-15 constructs |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012136231A1 (en) * | 2010-09-08 | 2012-10-11 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| CN104204194B (zh) * | 2011-12-22 | 2018-08-03 | 财团法人牧岩生命工学研究所 | 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物 |
| EP4339287A3 (en) * | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| AU2016374497B2 (en) * | 2015-12-16 | 2022-03-10 | The Walter And Eliza Hall Institute Of Medical Research | Inhibition of cytokine-induced SH2 protein in NK cells |
| JP7012645B2 (ja) * | 2016-01-11 | 2022-01-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラタンパク質および免疫治療の方法 |
| KR20180101540A (ko) * | 2016-01-15 | 2018-09-12 | 이투빅스 코포레이션 | T 세포 면역요법을 위한 방법 및 조성물 |
| EP3735984A1 (en) * | 2016-05-27 | 2020-11-11 | Etubics Corporation | Neoepitope vaccine compositions and methods of use thereof |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| EP3532075A4 (en) * | 2016-10-27 | 2020-07-08 | Intima Bioscience, Inc. | VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| EP3947647A4 (en) * | 2019-03-29 | 2023-01-04 | Board of Regents, The University of Texas System | METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF |
-
2019
- 2019-05-03 SG SG11202010763VA patent/SG11202010763VA/en unknown
- 2019-05-03 BR BR112020022010-8A patent/BR112020022010A2/pt not_active IP Right Cessation
- 2019-05-03 MX MX2020011697A patent/MX2020011697A/es unknown
- 2019-05-03 US US17/050,775 patent/US20210230548A1/en active Pending
- 2019-05-03 CN CN201980037453.2A patent/CN112292390A/zh active Pending
- 2019-05-03 NZ NZ770183A patent/NZ770183A/en unknown
- 2019-05-03 WO PCT/US2019/030721 patent/WO2019213610A1/en not_active Ceased
- 2019-05-03 KR KR1020207034764A patent/KR20210005240A/ko not_active Ceased
- 2019-05-03 AU AU2019262218A patent/AU2019262218B2/en active Active
- 2019-05-03 CA CA3099342A patent/CA3099342A1/en active Pending
- 2019-05-03 JP JP2020561821A patent/JP2021522798A/ja not_active Ceased
- 2019-05-03 EP EP19795874.7A patent/EP3788061A4/en active Pending
-
2020
- 2020-12-02 CO CONC2020/0015168A patent/CO2020015168A2/es unknown
-
2024
- 2024-01-05 JP JP2024000389A patent/JP2024045179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| US20240325450A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| Thomson et al. | Double-negative regulatory T cells: non-conventional regulators | |
| CN108025024B (zh) | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| JP2022512968A5 (enExample) | ||
| JP2021501604A5 (enExample) | ||
| US20210113691A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| Hu et al. | Natural killer cell-based immunotherapy for cancer: advances and prospects | |
| WO2017219150A1 (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| CN110404061B (zh) | 改进的t细胞治疗方法 | |
| JP2024509095A5 (enExample) | ||
| TWI800522B (zh) | 醫藥重組受體組成物及方法 | |
| Mazza et al. | Prospects for development of induced pluripotent stem cell-derived CAR-targeted immunotherapies | |
| CN113396215A (zh) | 表达嵌合抗原受体(car)的骨髓浸润淋巴细胞(mil)、其制造方法及在疗法中使用的方法 | |
| JP2023521037A5 (enExample) | ||
| KR20230150833A (ko) | 세포 배양 방법 | |
| JP2022512948A (ja) | 表現型特性が向上したｔ細胞組成物 | |
| US20230030680A1 (en) | Chimeric gmcsf-il18 receptor | |
| Letessier et al. | Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer | |
| TW202309269A (zh) | 重組抗原呈現細胞 | |
| Yee | Adoptive therapy using antigen-specific T-cell clones | |
| US20160235827A1 (en) | Placental compositions for stimulation of immunity to pd-l1 |